203 related articles for article (PubMed ID: 32616888)
21. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
22. The role of the PI3K-AKT pathway in melanoma.
Davies MA
Cancer J; 2012; 18(2):142-7. PubMed ID: 22453015
[TBL] [Abstract][Full Text] [Related]
23. [Synergistic effect of targeted inhibition of MEK/ERK and PI3K/AKT survival signaling pathways on induction of apoptosis in melanoma].
Wang XY; Cheng Y; Du JP; Chen DG; Yang XS; Yang ZM; Huang N
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):355-61. PubMed ID: 24941796
[TBL] [Abstract][Full Text] [Related]
24. CD133 prevents colon cancer cell death induced by serum deprivation through activation of Akt-mediated protein synthesis and inhibition of apoptosis.
Mori Y; Takeuchi A; Miyagawa K; Yoda H; Soda H; Nabeya Y; Watanabe N; Ozaki T; Shimozato O
FEBS Open Bio; 2021 May; 11(5):1382-1394. PubMed ID: 33720534
[TBL] [Abstract][Full Text] [Related]
25. A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells.
Manoranjan B; Chokshi C; Venugopal C; Subapanditha M; Savage N; Tatari N; Provias JP; Murty NK; Moffat J; Doble BW; Singh SK
Oncogene; 2020 Feb; 39(7):1590-1599. PubMed ID: 31695152
[TBL] [Abstract][Full Text] [Related]
26. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
Malkomes P; Lunger I; Luetticke A; Oppermann E; Haetscher N; Serve H; Holzer K; Bechstein WO; Rieger MA
Ann Surg Oncol; 2016 Sep; 23(9):2849-57. PubMed ID: 27059026
[TBL] [Abstract][Full Text] [Related]
27. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
28. Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.
Shang C; Lang B; Meng LR
Cancer Biol Ther; 2018 Feb; 19(2):113-119. PubMed ID: 27791463
[TBL] [Abstract][Full Text] [Related]
29. [Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism].
Lin F; Yan W; Wen T; Wu GY
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):742-6. PubMed ID: 24378094
[TBL] [Abstract][Full Text] [Related]
30. PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133.
Matsushita M; Mori Y; Uchiumi K; Ogata T; Nakamura M; Yoda H; Soda H; Takiguchi N; Nabeya Y; Shimozato O; Ozaki T
FEBS Open Bio; 2019 May; 9(5):935-946. PubMed ID: 30947381
[TBL] [Abstract][Full Text] [Related]
31. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway.
Li B; Yuan Z; Jiang J; Rao Y
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30420490
[TBL] [Abstract][Full Text] [Related]
33. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Sinnberg T; Lasithiotakis K; Niessner H; Schittek B; Flaherty KT; Kulms D; Maczey E; Campos M; Gogel J; Garbe C; Meier F
J Invest Dermatol; 2009 Jun; 129(6):1500-15. PubMed ID: 19078992
[TBL] [Abstract][Full Text] [Related]
35. Notch1-MAPK Signaling Axis Regulates CD133
Kumar D; Kumar S; Gorain M; Tomar D; Patil HS; Radharani NNV; Kumar TVS; Patil TV; Thulasiram HV; Kundu GC
J Invest Dermatol; 2016 Dec; 136(12):2462-2474. PubMed ID: 27476721
[TBL] [Abstract][Full Text] [Related]
36. A GLIS3-CD133-WNT-signaling axis regulates the self-renewal of adult murine pancreatic progenitor-like cells in colonies and organoids.
Tremblay JR; Lopez K; Ku HT
J Biol Chem; 2019 Nov; 294(45):16634-16649. PubMed ID: 31533988
[TBL] [Abstract][Full Text] [Related]
37. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
38. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
39. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
He K; Xu T; Xu Y; Ring A; Kahn M; Goldkorn A
Int J Cancer; 2014 Jan; 134(1):43-54. PubMed ID: 23784558
[TBL] [Abstract][Full Text] [Related]
40. The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
Schneider P; Schön M; Pletz N; Seitz CS; Liu N; Ziegelbauer K; Zachmann K; Emmert S; Schön MP
Exp Dermatol; 2014 Aug; 23(8):579-84. PubMed ID: 24942196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
